US20030194807A1
(en)
*
|
1992-11-02 |
2003-10-16 |
Roberto Crea |
Walk-through mutagenesis
|
ATE210724T1
(de)
*
|
1993-04-09 |
2001-12-15 |
Catalytic Antibodies Inc |
Selektion von genen katalytischer antikörper
|
US6309883B1
(en)
|
1994-02-17 |
2001-10-30 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6995017B1
(en)
|
1994-02-17 |
2006-02-07 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6165793A
(en)
*
|
1996-03-25 |
2000-12-26 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US20060257890A1
(en)
|
1996-05-20 |
2006-11-16 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5683987A
(en)
*
|
1994-07-12 |
1997-11-04 |
The Board Of Regents Of The University Of Nebraska |
Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
|
US6063562A
(en)
*
|
1994-09-16 |
2000-05-16 |
Sepracor, Inc. |
In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
|
US5602021A
(en)
*
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US6238884B1
(en)
|
1995-12-07 |
2001-05-29 |
Diversa Corporation |
End selection in directed evolution
|
US20030219752A1
(en)
*
|
1995-12-07 |
2003-11-27 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
US6537776B1
(en)
*
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
CN1117842C
(zh)
*
|
1996-12-20 |
2003-08-13 |
尤尼利弗公司 |
酶促漂白组合物
|
US6153410A
(en)
*
|
1997-03-25 |
2000-11-28 |
California Institute Of Technology |
Recombination of polynucleotide sequences using random or defined primers
|
DE19731990A1
(de)
*
|
1997-07-25 |
1999-01-28 |
Studiengesellschaft Kohle Mbh |
Verfahren zur Herstellung und Identifizierung von neuen Hydrolasen mit verbesserten Eigenschaften
|
US6670127B2
(en)
*
|
1997-09-16 |
2003-12-30 |
Egea Biosciences, Inc. |
Method for assembly of a polynucleotide encoding a target polypeptide
|
WO1999038961A1
(en)
*
|
1998-01-30 |
1999-08-05 |
Sepracor Inc. |
Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted thereagainst
|
US7153655B2
(en)
*
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
US20090130718A1
(en)
*
|
1999-02-04 |
2009-05-21 |
Diversa Corporation |
Gene site saturation mutagenesis
|
EP1073710A4
(de)
*
|
1999-02-04 |
2007-12-19 |
Verenium Corp |
Nicht-stochastische erzeugung von genetischen impfstoffen und enzymen
|
JP3399518B2
(ja)
*
|
1999-03-03 |
2003-04-21 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
半導体構造およびその製造方法
|
IL145165A0
(en)
*
|
1999-03-09 |
2002-06-30 |
Diversa Corp |
End selection in directed evolution
|
US6251604B1
(en)
*
|
1999-08-13 |
2001-06-26 |
Genopsys, Inc. |
Random mutagenesis and amplification of nucleic acid
|
US7115712B1
(en)
*
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
WO2001064864A2
(en)
*
|
2000-02-28 |
2001-09-07 |
Maxygen, Inc. |
Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
|
AU2001287273A1
(en)
*
|
2000-03-24 |
2001-10-08 |
Maxygen, Inc. |
Methods for modulating cellular and organismal phenotypes
|
ES2531551T3
(es)
*
|
2000-04-17 |
2015-03-17 |
Dyax Corp. |
Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
US6764826B2
(en)
*
|
2000-06-08 |
2004-07-20 |
Board Of Regents, The University Of Texas System |
Inhibitors of C-reactive protein induced inflammation
|
FR2813314B1
(fr)
*
|
2000-08-25 |
2004-05-07 |
Biomethodes |
Procede de mutagenese dirigee massive
|
AU2004260931B9
(en)
|
2003-04-29 |
2012-01-19 |
E.I. Du Pont De Nemours And Company |
Novel glyphosate-N-acetyltransferase (GAT) genes
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
WO2002061071A2
(en)
|
2000-12-18 |
2002-08-08 |
Dyax Corp. |
Focused libraries of genetic packages
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
JP2004532038A
(ja)
*
|
2001-05-17 |
2004-10-21 |
ディヴァーサ コーポレイション |
新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
|
SE0102327D0
(sv)
|
2001-06-28 |
2001-06-28 |
Active Biotech Ab |
A novel engineered superantigen for human therapy
|
US7647184B2
(en)
*
|
2001-08-27 |
2010-01-12 |
Hanall Pharmaceuticals, Co. Ltd |
High throughput directed evolution by rational mutagenesis
|
US20040096826A1
(en)
*
|
2002-01-30 |
2004-05-20 |
Evans Glen A. |
Methods for creating recombination products between nucleotide sequences
|
US20030224404A1
(en)
*
|
2002-02-25 |
2003-12-04 |
Manuel Vega |
High throughput directed evolution of nucleic acids by rational mutagenesis
|
US20030199068A1
(en)
*
|
2002-03-05 |
2003-10-23 |
Bott Richard R. |
High throughput mutagenesis screening method
|
US20030171543A1
(en)
*
|
2002-03-05 |
2003-09-11 |
Bott Richard R. |
High throughput mutagenesis screening method
|
DE60328674D1
(de)
|
2002-04-17 |
2009-09-17 |
Bioren Inc |
Universelle banken für immunoglobuline
|
NZ535928A
(en)
*
|
2002-04-17 |
2006-09-29 |
Roberto Crea |
Determining the ratio of prototype nucleotides to predetermined nucleotides, which is preferably greater than 1:1, by doping in walk-through mutagenesis
|
ES2285118T5
(es)
*
|
2002-05-17 |
2012-09-21 |
Alligator Bioscience Ab |
Un método para el desarrollo molecular in vitro de una función proteica.
|
EP1576151A4
(de)
|
2002-08-06 |
2006-05-17 |
Verdia Inc |
Ap1-aminoxidase-varianten
|
KR101170653B1
(ko)
|
2002-08-12 |
2012-08-03 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
WO2004016586A2
(en)
*
|
2002-08-16 |
2004-02-26 |
Board Of Regents The University Of Texas System |
Compositions and methods related to flavivirus envelope protein domain iii antigens
|
ES2343518T3
(es)
|
2002-09-09 |
2010-08-03 |
Hanall Biopharma Co., Ltd. |
Polipeptidos interferon alfa modificados resistentes a proteasas.
|
ATE471337T1
(de)
|
2003-04-02 |
2010-07-15 |
Univ Texas |
Anti-tumor effekt von bik-mutanten
|
CA2542192C
(en)
*
|
2003-06-27 |
2013-05-28 |
Bioren, Inc. |
Look-through mutagenesis
|
DK1664343T3
(da)
|
2003-09-09 |
2014-08-11 |
Integrigen Inc |
Fremgangsmåder og sammensætninger til generering af kimcelle humane antistofgener
|
MX2007000104A
(es)
*
|
2004-07-06 |
2007-07-18 |
Bioren Inc |
Anticuerpos anti-tnf-? de gran afinidad y metodo.
|
US9012369B2
(en)
|
2004-07-06 |
2015-04-21 |
Pfizer Inc. |
Look-through mutagenesis for developing altered polypeptides with enhanced properties
|
EP1781680B8
(de)
|
2004-07-06 |
2016-05-18 |
Bioren, LLC |
Universelle antikörperbibliotheken
|
CA2605697A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Bioren, Inc. |
Method of producing human igg antibodies with enhanced effector functions
|
US20070026012A1
(en)
|
2005-08-01 |
2007-02-01 |
Cornell Research Foundation, Inc. |
Compositions and methods for monitoring and altering protein folding and solubility
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
CA2621982C
(en)
*
|
2005-09-07 |
2017-11-28 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
US8716195B2
(en)
|
2005-11-14 |
2014-05-06 |
Bioren, Inc. |
Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
|
GB2432366B
(en)
*
|
2005-11-19 |
2007-11-21 |
Alligator Bioscience Ab |
A method for in vitro molecular evolution of protein function
|
EP2522678A1
(de)
|
2006-05-15 |
2012-11-14 |
Sea Lane Biotechnologies, LLC |
Neutralisierung von Antikörpern der Influenza-Viren
|
US20080108513A1
(en)
*
|
2006-06-01 |
2008-05-08 |
Northwestern University |
Cellular Arrays
|
CA2666599A1
(en)
|
2006-08-18 |
2008-02-21 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
US8481023B2
(en)
|
2006-09-15 |
2013-07-09 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
MX2009004221A
(es)
*
|
2006-10-20 |
2009-09-10 |
Univ Arizona State |
Cianobacterias modificadas.
|
EP2118281A2
(de)
*
|
2007-02-12 |
2009-11-18 |
Codexis, Inc. |
Struktur-wirkungs-beziehungen
|
US20100106585A1
(en)
*
|
2007-04-17 |
2010-04-29 |
American Express Travel Related Services Company, Inc. |
System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
|
JP5781762B2
(ja)
*
|
2007-08-10 |
2015-09-24 |
プロテリックス、インク |
ユニバーサルiii型フィブロネクチン結合ドメインのライブラリ
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8680019B2
(en)
*
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
WO2009036379A2
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
US20110189203A1
(en)
|
2007-11-27 |
2011-08-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
EP2281078B1
(de)
*
|
2008-04-24 |
2014-10-22 |
Dyax Corporation |
Bibliotheken von genetischen packungen, umfassend neue hc-cdr1, -cdr2, und -cdr3, und neue lc-cdr1-, -cdr2- und -cdr3-designs
|
PT2274331E
(pt)
|
2008-05-02 |
2014-02-27 |
Novartis Ag |
Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
|
EP3629022A1
(de)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Proteinscreeningverfahren
|
JP5230397B2
(ja)
*
|
2008-12-18 |
2013-07-10 |
独立行政法人科学技術振興機構 |
抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
|
WO2010111707A1
(en)
|
2009-03-27 |
2010-09-30 |
Sapphire Energy, Inc. |
Variant isoprenoid producing enzymes and uses thereof
|
WO2010115998A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
EP2417162A2
(de)
|
2009-04-10 |
2012-02-15 |
Ablynx N.V. |
Verbesserte, gegen il-6r gerichtete amiinosäuresequenzen und polypeptide, die diese enthalten, zur behandlung von krankheiten und erkrankungen, die mit il-6r in zusammenhang stehen
|
MX340541B
(es)
|
2009-06-05 |
2016-07-13 |
Alblynx Nv |
Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
|
CA2773564A1
(en)
*
|
2009-09-14 |
2011-03-17 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
KR101838472B1
(ko)
|
2009-09-14 |
2018-03-15 |
신라젠(주) |
종양 용해 백시니아 바이러스 병용 암 치료요법
|
ES2691717T3
(es)
|
2009-10-30 |
2018-11-28 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
MX365946B
(es)
|
2009-12-10 |
2019-06-19 |
Turnstone Lp |
Rabdovirus oncolitico.
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
DK3741883T3
(da)
|
2010-07-16 |
2023-02-20 |
Adimab Llc |
Antistofbiblioteker
|
WO2012016245A2
(en)
|
2010-07-30 |
2012-02-02 |
Novartis Ag |
Fibronectin cradle molecules and libraries thereof
|
AU2011289286B2
(en)
|
2010-08-13 |
2015-02-12 |
Pioneer Hi-Bred International, Inc. |
Methods and compositions for targeting sequences of interest to the chloroplast
|
JP6121910B2
(ja)
|
2011-01-04 |
2017-04-26 |
シラジェン バイオセラピューティクス インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
|
US9364532B2
(en)
|
2011-06-08 |
2016-06-14 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
RU2019133467A
(ru)
|
2011-10-11 |
2020-07-06 |
МЕДИММЬЮН, ЭлЭлСи |
Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
|
EP2820043B1
(de)
|
2012-03-02 |
2020-01-15 |
Ablynx N.V. |
Biparatopische pseudomonas aeruginoas pcrv bindende variable einzeldomänen antikörper
|
CA2872096A1
(en)
|
2012-05-04 |
2013-11-07 |
E. I. Du Pont De Nemours And Company |
Compositions and methods comprising sequences having meganuclease activity
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
WO2014153234A1
(en)
|
2013-03-14 |
2014-09-25 |
Pioneer Hi-Bred International, Inc. |
Compositions having dicamba decarboxylase activity and methods of use
|
CA2904537A1
(en)
|
2013-03-14 |
2014-09-25 |
Pioneer Hi-Bred International, Inc. |
Compositions having dicamba decarboxylase activity and methods of use
|
CN107074954A
(zh)
|
2014-10-21 |
2017-08-18 |
埃博灵克斯股份有限公司 |
Il‑6r相关疾病的治疗
|
CN107428817B
(zh)
|
2015-03-12 |
2022-07-12 |
免疫医疗有限责任公司 |
纯化白蛋白融合蛋白的方法
|
US10787500B2
(en)
|
2015-04-10 |
2020-09-29 |
Adimab, Llc |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
US10526597B2
(en)
|
2015-05-21 |
2020-01-07 |
Full Spectrum Genetics, Inc. |
Method of improving characteristics of proteins
|
WO2018005559A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
US11891634B2
(en)
|
2017-06-23 |
2024-02-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
PDE5A destabilizing domains
|
WO2019118918A1
(en)
|
2017-12-15 |
2019-06-20 |
Aleta Biotherapeutics Inc. |
Cd19 variants
|